LNSR LENSAR, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1320350 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY29.3%
TTM net income YoY-292.7%
TTM EPS YoY-289.8%
Revenue 3-yr CAGR16.5%
Net income 3-yr CAGR—
Margins
Gross margin47.2%
Operating margin-25.0%
Net margin-84.5%
FCF margin-9.0%
EBITDA margin-19.3%
Returns
ROE-16,631.7%
ROA-74.8%
ROIC (approx.)—
Asset turnover0.89x
Leverage & solvency
Liabilities / assets113.2%
Debt / equity—
Current ratio1.52x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.10x
Accruals ratio-67.0%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $58.44M | $53.49M |
| Cost of revenue | $31.31M | $27.64M |
| Gross profit | $27.12M | $25.85M |
| R&D expense | $5.62M | $5.33M |
| SG&A expense | $45.16M | $26.49M |
| Operating income | -$24.58M | -$10.66M |
| Pretax income | -$34.28M | -$31.40M |
| Net income | -$34.28M | -$31.40M |
| EBITDA | -$21.00M | -$7.70M |
| EPS (basic) | -2.87 | -2.73 |
| EPS (diluted) | -2.87 | -2.73 |
| Weighted avg. shares (diluted) | 11.96M | 11.52M |
| Balance sheet | ||
| Cash & equivalents | $12.97M | $16.26M |
| Short-term investments | $5.00M | $6.19M |
| Receivables | $6.38M | $6.08M |
| Inventory | $21.52M | $11.43M |
| Current assets | $46.77M | $41.98M |
| PP&E, net | $505,000 | $664,000 |
| Intangibles | $5.19M | $6.11M |
| Total assets | $71.43M | $66.30M |
| Current liabilities | $40.57M | $15.00M |
| Total liabilities | $83.67M | $47.65M |
| Shareholders' equity | -$26.02M | $4.86M |
| Shares outstanding | 11.99M | 11.65M |
| Cash flow statement | ||
| Operating cash flow | -$14.83M | -$2.27M |
| Capital expenditure | $83,000 | $156,000 |
| Free cash flow | -$14.91M | -$2.43M |
| Investing cash flow | $1.28M | -$2.16M |
| Financing cash flow | $10.26M | $78,000 |
| Depreciation & amortization | $3.58M | $2.96M |
| Stock-based compensation | $3.14M | $2.67M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.